Each week we summarize new research on longevity, peptides, and regenerative medicine in plain language. Every summary includes the studies it is based on so you can read the source yourself. This week covers three topics.
Rapamycin: an old transplant drug tested for healthy aging
- Rapamycin is a prescription drug that lowers the activity of a cell pathway called mTOR. It is normally used to stop the body from rejecting a transplanted organ.
- A 2025 trial called PEARL reported that low, occasional doses appeared safe over one year in healthy adults over 50, though stomach upset was more common in the groups taking the drug.
- A 2026 study reported that low-dose rapamycin lowered p21, a marker of “aging” cells, in immune cells. No human trial has shown that rapamycin makes people live longer.
mTOR is a switch inside cells that tells them to grow. Dialing it down appears to trigger cellular “housekeeping.” Rapamycin turns that switch down, which is why researchers study it for aging.
The animal evidence is unusually strong. Rapamycin extends lifespan in yeast, worms, flies, and mice, and a program that repeats aging experiments across independent labs has confirmed the mouse result at three separate sites.
Human evidence is much earlier. The PEARL trial, published in 2025, tested low intermittent doses in healthy older adults for a year. It found the regimen was generally safe, with more gastrointestinal symptoms in the rapamycin groups and small, sex-specific hints of benefit for muscle and pain in women. A 2026 study added that the drug reduced p21, a sign of cellular senescence, in immune cells.
Two cautions. Rapamycin is not approved by the FDA for aging or longevity, so this use is off-label. And no human trial has used lifespan or a hard health outcome as its main goal, so the longevity claims remain unproven in people.
- "Influence of rapamycin on safety and healthspan metrics after one year: the PEARL trial." Aging (Albany NY), 2025. aging-us.com
- "Low-dose rapamycin reduces markers of cellular senescence in older adults." Aging Cell, 2026. onlinelibrary.wiley.com
GLP-1 weight-loss drugs and muscle: can you keep the muscle?
- GLP-1 drugs such as semaglutide are peptide-based medicines that cause large weight loss. Some of the weight lost is muscle — by some estimates up to about 40 percent.
- A 2026 trial that combined semaglutide with an experimental antibody called bimagrumab produced large weight loss while keeping lean mass, including muscle.
- Other 2026 research suggests that for many people, GLP-1 weight loss does not cause a worse-than-expected loss of muscle strength.
When people lose weight by any method, some of the loss comes from muscle, not just fat. Because GLP-1 drugs cause fast, large weight loss, doctors have asked how much muscle goes with it.
The BELIEVE trial, reported in 2026, paired semaglutide with bimagrumab, which blocks a signal that breaks muscle down. Over 72 weeks the combination delivered substantial weight loss while preserving lean mass. Separately, a 2026 study in mice and humans found that weight loss from GLP-1 medicines did not lead to a disproportionate loss of muscle function, and in a small human pilot, strength held steady even as thigh muscle size shrank.
The practical takeaway most researchers give is not surprising: pair these drugs with enough protein and resistance exercise. The muscle-sparing combinations are promising but new, and longer studies are still needed.
- "Bimagrumab plus semaglutide for weight loss and lean-mass preservation: the BELIEVE trial." Nature Medicine, 2026. nature.com
- "Weight loss with GLP-1 medicines does not result in disproportionate loss of muscle mass or function." Cell Reports Medicine, 2026. cell.com
Exosomes for knee arthritis: promising, but mostly in the lab
- Exosomes are tiny packages that cells release to carry signals to other cells.
- In lab dishes and animal studies of osteoarthritis, stem-cell-derived exosomes reduced inflammation and helped protect cartilage.
- As of 2026, strong human trials are still limited, and there is no standard dose or preparation method.
Instead of injecting stem cells, some researchers are testing the tiny signaling packages those cells release, called exosomes. The idea is that the signals, not the cells themselves, do much of the healing work.
Reviews published in 2026 describe encouraging results: exosomes from fat- or cord-derived stem cells lowered inflammation and slowed cartilage breakdown in cell and animal models of knee osteoarthritis. They may act by delivering small pieces of genetic material that calm overactive immune cells.
The honest status is early. Most of this work is still in dishes or small animals, larger human trials are scarce, and the field has not agreed on how many exosomes to use or how to prepare them. It is a promising direction, not a proven treatment.
- "Recent advances in the use of stem cell-derived exosomes for joint regeneration." Molecular Biology Reports, 2026. springer.com
- "Global clinical trial landscape of stem cell-based therapies for osteoarthritis." Frontiers in Cell and Developmental Biology, 2026. frontiersin.org